Functional Selectivity of NK1 Receptor Signaling: Peptide Agonists Can Preferentially Produce Receptor Activation or Desensitization

  1. Mark A. Simmons
  1. Department of Physiology and Pharmacology, Northeastern Ohio Universities College of Medicine, Rootstown, Ohio
  1. Address correspondence to:
    Dr. Mark A. Simmons, Department of Physiology and Pharmacology, Northeastern Ohio Universities College of Medicine, 4209 State Route 44, Rootstown, OH 44272. E-mail: simmons{at}neoucom.edu

Abstract

A cascade of events follows binding of an agonist ligand to the tachykinin NK1 receptor. These events include activation of multiple signal transduction pathways as well as cellular modulation of receptor function by the process of desensitization. This study examines the differences in the abilities of naturally occurring peptide agonist ligands of the tachykinin NK1 receptor to preferentially direct signaling through the receptor to produce signal activation versus receptor desensitization. The differential effects of tachykinin peptides with respect to ligand competition binding, receptor-G protein coupling, intracellular Ca2+ elevations, and receptor desensitization have been measured. In relation to its potency in competition binding studies, substance P produces desensitization at lower concentrations, whereas higher concentrations are required to elicit a Ca2+ response. In contrast to this, a related peptide, ranatachykinin C, is more effective at activating a Ca2+ response relative to its ability to produce desensitization. This difference in functional selectivity is conserved for an amphibian and two mammalian ortholog tachykinin receptors. The present study demonstrates that peptide agonist ligands of NK1 receptors can preferentially produce signal activation or desensitization.

Footnotes

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

  • doi:10.1124/jpet.106.109512.

  • ABBREVIATIONS: SP, substance P; RTK, ranatachykinin; CHO, Chinese hamster ovary; GTPγS, guanosine 5′-3-O-(thio)triphosphate.

    • Received June 16, 2006.
    • Accepted August 16, 2006.
« Previous | Next Article »Table of Contents